Home/Pipeline/Anti-platelet

Anti-platelet

Cardiovascular diseases

DevelopmentActive

Key Facts

Indication

Cardiovascular diseases

Phase

Development

Status

Active

Company

Dawah Pharmaceuticals

About Dawah Pharmaceuticals

Dawah Pharmaceuticals is a commercial-stage generic drug company employing a capital-light, partnership-driven model to bring essential medicines to market. Its strategy centers on identifying and filling supply gaps for sterile injectable and ophthalmic products by collaborating with top-tier international CMOs, primarily for U.S. market entry. Backed by leadership with decades of healthcare experience, the company is building a diverse pipeline targeting therapeutic areas like critical care, oncology, and CNS disorders, with several product launches projected from 2026 onward. Dawah's approach combines U.S. regulatory expertise with cost-effective global manufacturing to improve drug access and affordability.

View full company profile

Therapeutic Areas

Critical Care Oncology Mental Health Infectious Disease Ophthalmology Cardiovascular Metabolic Disorders Neurology Pain Management

Other Cardiovascular diseases Drugs

Drug	Company	Phase	Status
Autonomic Therapy Initiative (ATI)	BIOS Health	Pre-clinical	Active
Cardiology Diagnostics Program	Aptus Biosciences	Discovery	Active
Cardiovascular Collaboration	Unnatural Products	Discovery	Active
SBX 2000	Stramsen Biotech	Early-stage Clinical	Active
Not specified on provided pages	Cadila Pharmaceuticals	Commercial (World's First Claim)	Marketed
Cardiovascular Biomarkers R&D	Firalis	Development	Active
EPS222	Eusol Biotech	Preclinical	Active